Alphamab Oncology

https://www.alphamabonc.com/en/

Alphamab Oncology (9966.HK), headquartered in Suzhou, China, is a leading clinical-stage biopharmaceutical company deeply dedicated to the discovery, development, manufacturing, and commercialization of next-generation cancer therapeutics. Founded in 2008 by Dr. Ting Xu, the company operates with a rigorous mission to address significant unmet medical needs in oncology by engineering biologics that offer greater precision, lower toxicity, and superior efficacy. Through its fully integrated proprietary platforms in protein engineering and bispecifics, Alphamab Oncology aims to deliver world-class, China-innovated cancer therapies that fundamentally transform patient survival and quality of life on a global scale.

The company fundamentally disrupted the immuno-oncology landscape with the launch of its flagship product, ENWEIDA® (Envafolimab), which made history as the world’s first subcutaneously injected PD-L1 inhibitor. Beyond its commercialized portfolio, Alphamab is aggressively advancing a massive clinical pipeline anchored by highly specialized bispecific antibodies and advanced Antibody-Drug Conjugates (ADCs). Its lead bispecific asset, KN026 (an anti-HER2 antibody), is currently navigating pivotal Phase III trials for gastric and breast cancers and has already received Breakthrough Therapy Designation from both U.S. and Chinese regulators. Furthermore, the company leverages its proprietary site-specific glycan conjugation technology to develop highly sophisticated dual-target ADCs—such as the first-in-class TROP2/HER3 bispecific ADC JSKN016—designed to overcome resistance to traditional chemotherapies and targeted treatments.

Currently guided by Founder, Chairman, and CEO Dr. Ting Xu, alongside Chief Operating Officer Yang Liu, Alphamab Oncology is navigating a period of highly accelerated clinical execution. Moving through the first half of 2026, the company continues to demonstrate robust operational momentum following a resilient 2025 where it recorded RMB 566.24 million in total revenue. In April 2026, Alphamab announced a historic breakthrough when its Phase III trial for KN026 as a neoadjuvant treatment for breast cancer successfully met its primary endpoints. This momentum is set to be further highlighted at the prestigious 2026 ASCO Annual Meeting, where the company will present highly anticipated clinical data on JSKN016 in treating historically difficult HER2-negative breast cancers, cementing its status as an elite pioneer in the next generation of precision oncology.

Latest updates

Alphamab Oncology's ADC Data Could Broaden HER2-Negative Breast Cancer Treatment Options

Event summary

  • Alphamab Oncology will present Phase I data at ASCO 2026 (May 29-June 2) for JSKN016, a TROP2/HER3 bispecific ADC.
  • The study (JSKN016-101, NCT06592417) focuses on patients with HER2-negative locally advanced or metastatic breast cancer.
  • JSKN016 utilizes a proprietary glycan conjugation technology, resulting in a DAR of 4.
  • The company is also developing Envafolimab (KN035) and has an NMPA-reviewed HER2 bispecific antibody (KN026).

The big picture

The development of JSKN016 addresses a significant unmet need in HER2-negative breast cancer, a subtype for which treatment options are limited. Alphamab's focus on bispecific ADCs, combined with its proprietary platform technologies, positions it to compete in a rapidly evolving oncology market. The company's broader pipeline and partnerships suggest a strategy of diversified growth, but the success of JSKN016 will be a key driver of future valuation.

What we're watching

Clinical Efficacy
The ASCO presentation will be critical in assessing JSKN016’s true clinical benefit in HER2-negative breast cancer, particularly given the crowded ADC landscape.
Regulatory Pathway
Success in the ongoing Phase III trial for TNBC will be essential to securing regulatory approval and will likely dictate the speed of commercialization.
Combination Strategy
Alphamab's stated intention to combine JSKN016 with chemotherapy, IO, and targeted therapies will require careful sequencing and clinical trial design to demonstrate synergistic effects.

Alphamab's Breast Cancer Trial Data Poised to Challenge HER2 Treatment Landscape

Event summary

  • Alphamab Oncology's Phase III trial (KN026-004) of Anbenitamab (KN026) plus HB1801 demonstrated significantly improved total pathological complete response (tpCR) compared to the standard of care (trastuzumab + pertuzumab + docetaxel).
  • The trial results will be presented as a Late-Breaking Abstract Oral Presentation at the 2026 ASCO Annual Meeting on May 30, 2026.
  • KN026 is a HER2 bispecific antibody developed by Alphamab, co-developed with JMT-Bio, a subsidiary of CSPC Pharmaceutical Group.
  • Alphamab received an NDA acceptance from the NMPA for Anbenitamab for HER2-positive gastric cancer in September 2025, currently under review.

The big picture

The results represent a significant challenge to the established HER2-targeted therapies like trastuzumab and pertuzumab, potentially disrupting a multi-billion dollar market. Alphamab's CRIB platform, demonstrated here, positions the company as a leader in bispecific antibody development, a rapidly growing area of oncology. The partnership with CSPC provides Alphamab with access to a large and growing market in China, but also introduces complexities in revenue sharing and commercial strategy.

What we're watching

Clinical Validation
The full ASCO presentation data will be critical to assess the robustness of the tpCR improvement and the overall clinical benefit, beyond the topline results announced.
Regulatory Pathway
How the positive Phase III data impacts the ongoing NDA review for gastric cancer and the potential for accelerated approval pathways for breast cancer indications will be key.
Commercialization
The success of the partnership with CSPC in Mainland China will determine the commercial viability of KN026, given CSPC’s established distribution network.

Alphamab's Anbenitamab Combo Beats Standard HER2 Breast Cancer Treatment

Event summary

  • Alphamab Oncology's Anbenitamab (KN026) in combination with HB1801 met the primary endpoint (tpCR) in a Phase III trial (KN026-004) for neoadjuvant treatment of HER2-positive breast cancer.
  • The Anbenitamab combination demonstrated statistically and clinically significant improvement over the standard TCbHP regimen (trastuzumab, pertuzumab, docetaxel ± carboplatin).
  • The trial design included approximately 520 patients randomized 1:1, with plans for data presentation at an upcoming conference.
  • An adjuvant Phase III study (KN026-007) with 1,800 patients is underway, following first patient dosing in March 2026.

The big picture

Alphamab's success represents a significant advancement in HER2-positive breast cancer treatment, challenging the established standard of care and potentially disrupting the market dominated by Roche's trastuzumab and pertuzumab. The shorter treatment regimen offered by Anbenitamab, combined with the reduced toxicity profile of HB1801, could offer a compelling advantage for both patients and physicians. The partnership with CSPC and JMT-Bio provides a crucial pathway to commercialization within China, a rapidly growing oncology market.

What we're watching

Regulatory Approval
The speed of NMPA approval for Anbenitamab will be crucial for Alphamab’s revenue projections, particularly given the potential for inclusion on the national reimbursement drug list.
Competitive Landscape
How the market will react to the direct comparison data showing Anbenitamab’s superiority to the trastuzumab/pertuzumab combination will influence adoption rates and pricing strategies.
Adjuvant Data
The results of the adjuvant Phase III study (KN026-007) will be critical in establishing the long-term efficacy and overall clinical value of the Anbenitamab regimen.

Alphamab Oncology Nears Key Approvals, Pipeline Advances Amidst Rising R&D Spend

Event summary

  • Alphamab Oncology reported RMB 566.24 million in total revenue for FY2025, with RMB 130.13 million attributed to product revenue.
  • R&D expenditure increased significantly to RMB 572.16 million, representing a 41.57% year-on-year increase.
  • KN026 (Anbenitamab) received priority review status from the NMPA and is nearing market launch in China following successful GMP compliance inspection.
  • Multiple clinical trials for key pipeline candidates (JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021) are ongoing, with several achieving key milestones like POC confirmation and IND acceptance.

The big picture

Alphamab Oncology is aggressively expanding its oncology pipeline through a combination of internal innovation and strategic partnerships, positioning itself as a key player in the rapidly growing Chinese biopharmaceutical market. The company’s significant R&D investment, while driving pipeline progress, also contributes to ongoing losses and necessitates careful monitoring of commercialization timelines and regulatory outcomes to achieve profitability. The company’s reliance on regulatory approvals in China creates a degree of geopolitical risk.

What we're watching

Commercialization
The speed of KN026's market launch in China will be critical, as it represents Alphamab's first major commercial opportunity and will significantly impact near-term revenue projections.
R&D Efficiency
Given the substantial increase in R&D spending, investors will scrutinize the efficiency of Alphamab's pipeline advancement and the likelihood of further candidates reaching clinical stages.
Regulatory Risk
The success of Alphamab’s pipeline hinges on continued regulatory approvals in both China and international markets, exposing the company to potential delays or rejections.

Alphamab Advances HER2 Breast Cancer Trial with Novel Combination Therapy

Event summary

  • Alphamab Oncology initiated a Phase III clinical study (KN026-007) evaluating Anbenitamab (KN026) in combination with HB1801 and chemotherapy for adjuvant treatment of HER2-positive breast cancer.
  • The study aims to enroll approximately 1,800 patients with four or more positive lymph nodes following surgery.
  • Anbenitamab is co-developed with JMT-Bio, a subsidiary of CSPC Pharmaceutical Group.
  • The primary endpoint is investigator-assessed invasive disease-free survival (iDFS).

The big picture

The Phase III trial represents a significant step for Alphamab in its pursuit of a differentiated treatment for HER2-positive breast cancer, a market dominated by established therapies. The combination approach, leveraging Anbenitamab’s unique bispecific mechanism and CSPC’s albumin-bound docetaxel, aims to address the unmet need for improved outcomes in patients with high recurrence risk. Success hinges on demonstrating superior efficacy compared to current standards of care and navigating the complexities of the Chinese regulatory landscape.

What we're watching

Clinical Efficacy
The iDFS results will be critical in determining whether the combination therapy offers a significant advantage over existing treatments like trastuzumab and pertuzumab, particularly in the high-risk lymph node-positive patient population.
Commercialization
JMT-Bio’s ability to effectively commercialize Anbenitamab in Mainland China will be a key factor in Alphamab’s overall revenue generation, given the exclusivity agreement and the size of the Chinese market.
Regulatory Pathway
The NMPA's assessment of the Phase III data will influence the broader adoption of Anbenitamab and potentially impact the approval timelines for other pipeline candidates targeting HER2-positive cancers.

Alphamab Oncology Advances TNBC ADC Trial, Bolstering Pipeline

Event summary

  • Alphamab Oncology initiated a Phase III clinical study (JSKN016-301) for JSKN016, a TROP2/HER3 bispecific ADC, targeting triple-negative breast cancer (TNBC).
  • The trial will enroll approximately 60 sites across China and compare JSKN016 to treatment of physician's choice (TPC).
  • JSKN016 utilizes Alphamab’s proprietary single-domain antibody and bispecific antibody platforms, featuring a DAR4 ADC with glycan-specific conjugation.
  • TNBC, representing 15-20% of breast cancer cases, has limited treatment options, with current therapies yielding low response rates and short progression-free survival.

The big picture

The advancement of JSKN016 into Phase III represents a significant step for Alphamab Oncology, positioning it as a key player in the development of novel therapies for TNBC, a disease with substantial unmet medical need. The company's focus on proprietary antibody platforms and ADC technology, coupled with strategic partnerships, suggests a deliberate effort to build a globally competitive oncology franchise. Success with JSKN016 could unlock significant value, but the trial's outcome will be a key determinant of investor confidence.

What we're watching

Clinical Efficacy
The trial's success hinges on JSKN016 demonstrating statistically significant improvements in progression-free survival and overall survival compared to standard treatment, which will be closely scrutinized by investors.
Regulatory Pathway
Given China's evolving regulatory landscape for innovative therapies, the speed and approval conditions for JSKN016 will depend on the trial’s data and interactions with the NMPA.
Pipeline Breadth
Alphamab’s ability to advance its broader pipeline of ADCs and bispecific antibodies, including dual-payload candidates, will determine its long-term competitive positioning within the rapidly evolving oncology space.

Alphamab Oncology Appoints Seasoned CFO to Drive Capital Markets Strategy

Event summary

  • Alphamab Oncology appointed Fei Wang as Chief Financial Officer, effective immediately.
  • Mr. Wang brings over 20 years of financial management experience, including roles as CFO at AstraZeneca China and 3S Bio Inc.
  • He replaces an existing CFO, though the press release does not specify who or why.
  • Mr. Wang’s responsibilities include capital operations, investment, financing, and investor relations.
  • Alphamab Oncology is listed on the Hong Kong Stock Exchange (9966.HK).

The big picture

The appointment of a CFO with experience across both established pharma (AstraZeneca) and biotech (3S Bio) suggests Alphamab is seeking to mature its financial operations and broaden its access to capital. This move is particularly relevant as Chinese biopharma companies increasingly seek to compete globally and navigate evolving regulatory landscapes. The company’s focus on advanced therapies like ADCs and bispecific antibodies requires significant investment, making a financially astute CFO essential for continued success.

What we're watching

Capital Allocation
How Mr. Wang’s experience with both private equity and large pharma will shape Alphamab’s investment strategy and R&D prioritization remains to be seen, particularly given the company's pipeline of ADC candidates.
Financing Strategy
Given the capital-intensive nature of biopharmaceutical development, whether Mr. Wang can successfully expand financing channels and secure favorable terms will be critical to Alphamab’s long-term growth.
Investor Perception
The market’s reaction to Mr. Wang’s appointment and his communication strategy will be a key indicator of investor confidence in Alphamab’s future prospects.

Alphamab Advances Novel PD-L1/VEGFR2 ADC into Phase 1 Trials

Event summary

  • Alphamab Oncology (9966.HK) initiated a Phase 1 clinical study (JSKN027-101) for JSKN027, a PD-L1/VEGFR2 bispecific ADC, in China.
  • JSKN027 is Alphamab’s fifth ADC candidate to enter clinical development.
  • The study will assess safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity, determining MTD/RP2D.
  • JSKN027 utilizes glycan-specific conjugation technology and a cleavable linker with a topoisomerase I inhibitor payload.

The big picture

Alphamab’s entry of JSKN027 into Phase 1 trials represents a significant advancement in the development of dual-target therapies for solid tumors, addressing the growing need for more effective cancer treatments. The company's focus on innovative ADC platforms, including glycan-specific conjugation, positions it to compete in a rapidly evolving oncology landscape. The first-in-class status of JSKN027, combined with Alphamab’s existing pipeline and partnerships, could drive significant value if clinical trials prove successful.

What we're watching

Clinical Efficacy
The initial clinical data regarding JSKN027’s efficacy in solid tumors will be crucial in determining its potential for broader application and future development.
Regulatory Pathway
The NMPA’s assessment of JSKN027’s safety and efficacy profile will influence the speed and likelihood of future approvals in China and potentially other markets.
Competitive Landscape
The success of JSKN027 will be weighed against other emerging bispecific ADCs and combination therapies targeting PD-L1 and VEGFR2, impacting Alphamab’s market positioning.

Alphamab Oncology Secures China Approval for Dual-Payload ADC JSKN021

Event summary

  • Alphamab Oncology received acceptance from the China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) for an Investigational New Drug (IND) application for JSKN021.
  • JSKN021 is a dual-payload bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, utilizing glycan-specific conjugation technology.
  • Preclinical data presented at the 2025 AACR meeting demonstrated JSKN021’s superior tumor inhibition efficacy compared to single-payload ADCs.
  • The Phase I clinical trial will assess safety, tolerability, pharmacokinetics, and antitumor activity in patients with advanced malignant solid tumors.
  • JSKN021 combines a topoisomerase I inhibitor (T01) and Monomethyl auristatin E (MMAE) payloads, designed to address tumor heterogeneity and resistance.

The big picture

Alphamab Oncology’s advancement of JSKN021 underscores the growing focus on next-generation ADCs with enhanced targeting and payload combinations to overcome treatment resistance in oncology. The acceptance of the IND application positions Alphamab to compete in a rapidly evolving market, particularly within China's expanding biopharmaceutical sector. The company’s existing portfolio, including Envafolimab, provides a foundation for continued innovation and strategic partnerships.

What we're watching

Clinical Outcomes
The success of the Phase I trial will hinge on demonstrating acceptable safety and tolerability, alongside preliminary evidence of antitumor activity, which will dictate progression to Phase II.
Regulatory Pathway
The NMPA’s review timeline and potential requirements for subsequent clinical phases will be crucial for Alphamab’s commercialization strategy in China.
Competitive Landscape
Given the crowded ADC market, Alphamab will need to clearly differentiate JSKN021’s dual-payload approach and demonstrate a significant clinical advantage over existing therapies.

Alphamab Oncology Adds CMC Veteran to Drive Commercialization

Event summary

  • Alphamab Oncology appointed Dr. Hongwei Wang as Chief Technology Officer (CTO), effective March 11, 2026.
  • Dr. Wang will oversee Process Development, Analytical Development, Production, and Quality departments.
  • Prior to Alphamab, Dr. Wang held leadership roles at Jiangsu Hengrui Pharmaceuticals and its subsidiary, Suzhou Suncadia Biopharmaceuticals.
  • Dr. Wang has a track record of leading the approval and commercialization of six biologics and advancing over 20 candidates into clinical stages.

The big picture

Alphamab’s strategic move to recruit a seasoned CMC expert like Dr. Wang signals a shift towards commercialization and manufacturing scale-up, a common challenge for innovative biopharma companies. The appointment addresses the critical need for robust manufacturing processes as Alphamab transitions from R&D to a commercial-stage enterprise, particularly given the imminent launch of KN026 and the pending NDA submission for JSKN003. This hire is a bet on operational excellence to support a pipeline of increasingly complex therapies.

What we're watching

Regulatory Approval
The success of KN026’s regulatory pathway will be a key indicator of Alphamab’s ability to execute on its commercial strategy, given the CTO’s focus on CMC and manufacturing.
Manufacturing Capacity
Whether Alphamab can rapidly scale its manufacturing capabilities to meet anticipated demand for KN026 and other pipeline candidates will determine its ability to capitalize on its innovation.
Pipeline Progression
The speed at which Alphamab advances its next-generation ADC pipelines, particularly dual-payload candidates, will reveal the effectiveness of the new CTO’s leadership in process development.

Alphamab's Anbenitamab Phase III Data Bolsters Second-Line Gastric Cancer Treatment Landscape

Event summary

  • Alphamab Oncology published Phase III results for Anbenitamab (KN026) in *Annals of Oncology*, a top-tier journal with an impact factor of 65.4.
  • The study demonstrated a significant improvement in progression-free survival (PFS) – 7.1 months vs. 2.7 months (HR 0.25, p<0.0001) – and overall survival (OS) – 19.6 months vs. 11.5 months (HR 0.29, p<0.0001) – compared to standard of care.
  • The trial enrolled patients with HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) who had failed first-line trastuzumab-based therapy.
  • The NMPA accepted an NDA for Anbenitamab in September 2025, and it has received Breakthrough Therapy Designation for this indication.
  • Alphamab has a partnership with JMT-Bio for development and commercialization of KN026 in Mainland China.

The big picture

Alphamab's Anbenitamab represents a significant advancement in the treatment of HER2-positive gastric cancer, a disease with limited therapeutic options after first-line therapy failure. The robust Phase III data, published in a high-impact journal, positions Anbenitamab to potentially disrupt the existing treatment paradigm and generate substantial revenue for Alphamab. This success underscores the growing importance of bispecific antibodies in oncology and highlights China's increasing role in innovative drug development.

What we're watching

Regulatory Path
The speed of Anbenitamab's approval in other jurisdictions, beyond China, will hinge on the acceptance of these Phase III data and the FDA's assessment of its benefit-risk profile.
Commercial Execution
JMT-Bio’s ability to effectively commercialize Anbenitamab in China, given CSPC’s existing oncology portfolio, will be critical to Alphamab’s revenue projections.
Competitive Dynamics
The emergence of Anbenitamab as a potential standard of care will likely intensify competition within the second-line HER2-positive gastric cancer treatment space, potentially impacting pricing and market share.

Alphamab Advances JSKN033 Cervical Cancer Study with CDE Acceptance

Event summary

  • Alphamab Oncology received acceptance from the China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) for a Phase II clinical study of JSKN033.
  • JSKN033 is a subcutaneous co-formulation of a HER2 bispecific ADC (JSKN003) and a PD-L1 immune checkpoint inhibitor (Envafolimab).
  • The Phase II trial will evaluate JSKN033 in combination with platinum-based chemotherapy, with or without bevacizumab, as a first-line treatment for advanced cervical cancer.
  • Envafolimab, a component of JSKN033, is already approved in China as a subcutaneous PD-(L)1 inhibitor.

The big picture

Cervical cancer represents a significant unmet medical need, with limited treatment options for advanced stages. Alphamab’s JSKN033, combining an ADC and an immune checkpoint inhibitor in a subcutaneous formulation, aims to address this by leveraging synergistic mechanisms. The acceptance of this Phase II trial represents a key de-risking event for the company and validates its innovative approach to oncology drug development, particularly in the competitive Chinese market.

What we're watching

Clinical Efficacy
The trial results will be critical in determining JSKN033’s potential to improve outcomes in advanced cervical cancer, a disease with a poor prognosis.
Regulatory Pathway
The speed of NMPA approval for JSKN033, following successful Phase II results, will indicate the agency’s receptiveness to novel combination therapies.
Competitive Landscape
How Alphamab positions JSKN033 against existing platinum-based chemotherapy and immune checkpoint inhibitor regimens will influence its market adoption.
CID: 136